Bakri Sophie J, Kaiser Peter K
Cole Eye Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Expert Opin Pharmacother. 2004 Jan;5(1):195-203. doi: 10.1517/14656566.5.1.195.
This article reviews the pharmacotherapeutics of verteporfin (Visudyne), Novartis Pharma AG) used in ocular photodynamic therapy. The chemistry, pharmacokinetics and pharmacodynamics of the drug are reviewed. The article highlights and summarises the results of the multi-centre, randomised, controlled clinical trials with verteporfin to treat subfoveal choroidal neovascularisation in age-related macular degeneration, ocular histoplasmosis syndrome and pathologic myopia. In addition, the safety profile and side effects of verteporfin are discussed.
本文综述了用于眼部光动力疗法的维替泊芬（Visudyne，诺华制药有限公司）的药物治疗学。文中回顾了该药物的化学性质、药代动力学和药效学。本文重点介绍并总结了使用维替泊芬治疗年龄相关性黄斑变性、眼组织胞浆菌病综合征和病理性近视引起的黄斑下脉络膜新生血管的多中心、随机、对照临床试验结果。此外，还讨论了维替泊芬的安全性和副作用。
